This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717
Leung YK et al. (2006) Estrogen receptor (ER)- β isoforms: a key to understanding ER-β signaling. Proc Natl Acad Sci USA 103: 13162–13167
Speirs V et al. (2004) Oestrogen receptor β: what it means for patients with breast cancer. Lancet Oncol 5: 174–181. Erratum in: Lancet Oncol (2004) 5: 208
Palmieri C et al. (2004) The expression of ERβcx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 10: 2421–2428
Esslimai-Sahla M et al. (2005) Increased estrogen receptor βcx expression during mammary carcinogenesis. Clin Cancer Res 11: 3170–3174
Cui X et al. (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23: 7721–7735
Hopp TA et al. (2004) Low levels of estrogen receptor β protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 10: 7490–7499
Mote PA et al. (2002) Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat 72: 163–172
Loi S et al. (2007) The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. Crit Rev Oncol Hematol 61: 187–194
Goetz MP et al. (2006) A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res 12: 2080–2087
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Speirs, V., Shaaban, A. Hormone receptors in defining breast cancer prognosis—time for a rethink?. Nat Rev Clin Oncol 4, 204–205 (2007). https://doi.org/10.1038/ncponc0771
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0771
This article is cited by
-
Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer
Nature Clinical Practice Oncology (2008)